The largest randomized, multicenter clinical study, The United Kingdom Prospective Diabetes Study, was the first to demonstrate the ability of metformin to reduce the risk of macroangiopathy in patients with newly diagnosed diabetes and obesity or overweight, more than sulfonylureas or insulin. This evidence concerns the gene INS and diabetes mellitus.